SG Americas Securities
HAE icon

SG Americas Securities’s Haemonetics HAE Stock Holding History

SG Americas Securities’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27,400
Closed -$4K – 3391
2020
Q3 		$4K Buy
+27,400
New +$2.39M ﹤0.01% 2613

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SG Americas Securities's HAE Position: Q2 2026 in Review

SG Americas Securities reduced its Haemonetics (HAE) stake by 33% in Q2 2026, selling an estimated $97.1K and leaving 3,028 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #2743.

SG Americas Securities first reported a position in HAE in Q3 2013 and has held it in 40 quarters since. The position peaked at $14.2M in Q1 2020. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • SG Americas Securities held 3,028 shares of Haemonetics worth $227K as of Q2 2026.
  • SG Americas Securities sold 1,512 Haemonetics shares in Q2 2026, an estimated $97.1K.
  • Haemonetics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2743 holding.
  • SG Americas Securities first reported a position in Haemonetics in Q3 2013 and has held it in 40 quarters since.
  • SG Americas Securities's Haemonetics position peaked at $14.2M in Q1 2020.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.